Literature DB >> 12600440

Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome--an update.

Elaine E Tseng1, T T Wu, Charles J Yeo, Richard F Heitmiller.   

Abstract

We updated our surgical results and long-term outcome for prophylactic esophagectomy in patients with Barrett's esophagus and high-grade dysplasia (HGD) and determined the incidence of occult adenocarcinoma. Sixty consecutive patients with HGD who underwent esophagectomy had pre- and postoperative pathology examined at our institution from 1982 to 2001. We reviewed medical records to determine patient characteristics, surgical approach, operative morbidity and mortality, pathology, and length of stay. Patients and/or referring physicians were contacted to determine long-term outcome. Fifty-three men (88%) and 7 women (12%) were followed up for a median of 4.6 years. Transhiatal esophagectomy was performed in the majority of patients (82%). There was one operative death (1.7%) and 15 complications (29%). Median length of stay was 9 days. In 18 patients (30%), invasive adenocarcinoma was detected in the resected specimen. When examined by time periods, 43% (13/30) of patients were diagnosed with occult cancer from 1982-1994, whereas 17% (5/30) harbored occult malignancy from 1994-2001. All patients with adenocarcinoma in the recent interval had stage I disease, as opposed to only 61.5% of patients from the earlier study. Operative mortality declined from 3.3% to 0% over the two intervals as did mean length of stay from 14 days to 10 days. Five-year survival was excellent at 88%. Age and amount of preoperative weight loss were preoperative predictors of survival, whereas major postoperative complications and stage were postoperative predictors of outcome. Barrett's esophagus with high-grade dysplasia continues to be an indication for prophylactic esophagectomy. Overall prevalence of occult adenocarcinoma remains high. We have demonstrated a declining incidence of occult cancer and treatment of earlier stage adenocarcinoma when found in this population of patients treated with esophagectomy.

Entities:  

Mesh:

Year:  2003        PMID: 12600440     DOI: 10.1016/s1091-255x(02)00153-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

Review 1.  Management of Barrett's esophagus. The Society for Surgery of the Alimentary Tract (SSAT), American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE) Consensus Panel.

Authors: 
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.

Authors:  S Ramel; B J Reid; C A Sanchez; P L Blount; D S Levine; K Neshat; R C Haggitt; P J Dean; K Thor; P S Rabinovitch
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

3.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.

Authors:  M Miros; P Kerlin; N Walker
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

4.  p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.

Authors:  M Younes; R M Lebovitz; L V Lechago; J Lechago
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

5.  Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy?

Authors:  M Pera; V F Trastek; H A Carpenter; M S Allen; C Deschamps; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1992-08       Impact factor: 4.330

6.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.

Authors:  B J Reid; D S Levine; G Longton; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

7.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.

Authors:  A P Weston; A S Badr; R S Hassanein
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

8.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

9.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

10.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.

Authors:  B J Reid; R C Haggitt; C E Rubin; P S Rabinovitch
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

View more
  24 in total

1.  Esophagectomy for Barrett's esophagus: indications, techniques, and outcome.

Authors:  Ninh T Nguyen; Ken Chang; Tarlan Nahidi; Samuel E Wilson; James D Luketich
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

2.  Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.

Authors:  Dan Comay; Gord Blackhouse; Ron Goeree; David Armstrong; John K Marshall
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

3.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

4.  Predictive factors of coexisting cancer in Barrett's high-grade dysplasia.

Authors:  C Tharavej; J A Hagen; J H Peters; G Portale; J Lipham; S R DeMeester; C G Bremner; T R DeMeester
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

Review 5.  Endotherapy for Barrett's esophagus with high-grade dysplasia and intramucosal carcinoma.

Authors:  Drew B Schembre
Journal:  J Gastrointest Surg       Date:  2009-03-26       Impact factor: 3.452

Review 6.  SSAT controversies intramucosal esophageal cancer and high-grade dysplasia: which treatment? Surgical therapy: improved outcomes and piece of mind.

Authors:  Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2009-03-18       Impact factor: 3.452

Review 7.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

8.  Endoscopic mucosal resection for gastroesophageal cancer in a U.K. population. Long-term follow-up of a consecutive series.

Authors:  Andrew B C Crumley; James J Going; Kerryanne McEwan; Margaret McKernan; Jo-Etienne Abela; Christopher J Shearer; Adrian J Stanley; Robert C Stuart
Journal:  Surg Endosc       Date:  2010-07-10       Impact factor: 4.584

Review 9.  Minimally invasive esophagectomy for dysplastic Barrett's esophagus.

Authors:  Sheraz R Markar; George Hanna
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 10.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.